Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
6.36
+0.03 (0.47%)
Dec 12, 2025, 2:01 PM EST - Market open
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
206.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SGMT News
- 2 days ago - Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration - GlobeNewsWire
- 2 days ago - Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment - PRNewsWire
- 2 days ago - Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewsWire
- 24 days ago - Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts - Seeking Alpha
- 4 weeks ago - Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 7 weeks ago - Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - GlobeNewsWire